Coherus to Highlight Final P-II Study Data of Casdozokitug Regimen to Treat Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Shots:
- Coherus will present the P-II trial data of casdozokitug (10mg/kg; IV; Q3W) + Tecentriq (1200mg) + Avastin (15mg/kg) vs PBO for 1L LA/M HCC patients (n=30), in both viral & non-viral diseases, at ASCO GI 2025
- Study (as of Sep 2024) met its 1EP of safety & all 2EPs depicting 38% ORR (5 CRs, 6 confirmed PRs), 8.1mos. mPFS & DCR of 58.6% (n=29) as per RECIST v1.1, while 43% ORR (5 CRs, 7 confirmed PRs), 8.4mos. mPFS & DCR of 60.7% (n=28) as per mRECIST. Biomarker data showed IL-27 inhibition as well as NK & T-cells activation
- Coherus also initiated a new P-II trial (enrollment ongoing) assessing casdozo ± Loqtorzi & Avastin in LA/M HCC patients (n=~72) to find its safety, efficacy & dosing
Ref: Coherus | Image: Coherus
Related News:- Intas Pharmaceuticals to Acquire Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
